Benoist Chibaudel
Benoist Chibaudel
Service d'Oncologie Médicale, Institut Hospitalier Franco-Britannique - Levallois-Perret, France
Verified email at ihfb.org
Title
Cited by
Cited by
Year
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib …
P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ...
Jama 315 (17), 1844-1853, 2016
5412016
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, ...
Journal of Clinical Oncology 27 (34), 5727, 2009
4292009
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and …
T André, A De Gramont, D Vernerey, B Chibaudel, F Bonnetain, ...
Journal of clinical oncology 33 (35), 4176-4187, 2015
3892015
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter …
C Tournigand, T André, F Bonnetain, B Chibaudel, G Lledo, T Hickish, ...
J Clin Oncol 30 (27), 3353-3360, 2012
3152012
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the …
J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ...
The Lancet Oncology 17 (12), 1709-1719, 2016
2212016
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or …
P Hammel, F Huguet, JL Van Laethem, D Goldstein, B Glimelius, P Artru, ...
Journal of Clinical Oncology 31 (18_suppl), LBA4003-LBA4003, 2013
195*2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
FC Bidard, F Huguet, C Louvet, L Mineur, O Bouche, B Chibaudel, P Artru, ...
Annals of oncology 24 (8), 2057-2061, 2013
1572013
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients
MC Etienne‐Grimaldi, G Milano, F Maindrault‐Gœbel, B Chibaudel, ...
British journal of clinical pharmacology 69 (1), 58-66, 2010
1202010
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in …
S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ...
Annals of Oncology 26 (5), 873-879, 2015
1172015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
C Tournigand, B Chibaudel, B Samson, W Scheithauer, D Vernerey, ...
The Lancet Oncology 16 (15), 1493-1505, 2015
1152015
Therapeutic strategy in unresectable metastatic colorectal cancer
B Chibaudel, C Tournigand, T André, A de Gramont
Therapeutic advances in medical oncology 4 (2), 75-89, 2012
1052012
Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal …
F Maindrault-Goebel, G Lledo, B Chibaudel, L Mineur, T Andre, ...
Journal of Clinical Oncology 25 (18_suppl), 4013-4013, 2007
1032007
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and …
T André, H Blons, M Mabro, B Chibaudel, JB Bachet, C Tournigand, ...
Annals of oncology 24 (2), 412-419, 2013
922013
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials …
Q Shi, A De Gramont, A Grothey, J Zalcberg, B Chibaudel, HJ Schmoll, ...
Journal of Clinical Oncology 33 (1), 22, 2015
862015
Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy
G Manceau, S Imbeaud, R Thiébaut, F Liébaert, K Fontaine, F Rousseau, ...
Clinical Cancer Research 20 (12), 3338-3347, 2014
842014
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label …
T André, D Vernerey, L Mineur, J Bennouna, J Desrame, R Faroux, ...
Journal of clinical oncology 36 (15), 1469-1477, 2018
812018
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for …
A Anota, Z Hamidou, S Paget-Bailly, B Chibaudel, C Bascoul-Mollevi, ...
Quality of Life Research 24 (1), 5-18, 2015
802015
Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database
LA Renfro, F Loupakis, RA Adams, MT Seymour, V Heinemann, ...
Journal of Clinical Oncology 34 (2), 144, 2016
792016
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
B Chibaudel, F Bonnetain, C Tournigand, L Bengrine-Lefevre, L Teixeira, ...
The oncologist 16 (9), 1228, 2011
752011
OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A …
F Maindrault-Goebel, G Lledo, B Chibaudel, L Mineur, T Andre, ...
Journal of Clinical Oncology 24 (18_suppl), 3504-3504, 2006
662006
The system can't perform the operation now. Try again later.
Articles 1–20